Upstream Bio reports positive Phase 2 VALIANT results: verekitug reduces asthma exacerbations by 56% and 39%

Upstream Bio, Inc.

Verekitug 100 mg q12w reduced AAER by 56% (p<0.0003); 400 mg q24w reduced AAER by 39% (p<0.02) vs placebo.
Placebo-adjusted FEV1 improvement of 122 mL (q12w) and 139 mL (q24w) at week 60.
FeNO suppressed vs placebo by 20.4 ppb (q12w) and 26.3 ppb (q24w); mean reductions of 43-45% from baseline.
Verekitug well tolerated with safety consistent with prior studies; >90% of eligible patients rolled over to VALOUR LTE.
Company plans to advance verekitug into Phase 3 trials in severe asthma and CRSwNP after regulatory interactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.